Top managers of Meros Pharm are “Leaders of the…

Top managers of Meros Pharm, founder Nasim Komilov and CEO Hayyom Sharapov have become the winners of the contest for the Eurasian Pharma Awards 2023 in the nomination “Leader of the Year”.

The competition for the Eurasian Pharma Awards was held for the fourth time by the Global Pharmaceutical Leaders’ Club as a part of the Eurasian Pharmaceutical Summit. 97 applications for awards were received from pharmaceutical production companies, distributors and pharmacy chains.

Meros Pharm has been providing citizens of the Republic of Uzbekistan with medicines for 15 years and has become the market leader with a share of more than 30%. The portfolio of Meros Pharm includes medicines from more than 400 suppliers. The company provides jobs to more than 1200 Uzbek people, who are proud of their involvement in supporting the health of their compatriots.

Eurasian Pharmaceutical Summit 2023 in Samarkand: key topics and…

The Eurasian Pharmaceutical Summit, which was held by the Global Pharmaceutical Leaders’ Club in Samarkand at the end of September, brought together more than 300 experts and leaders of the pharmaceutical industry to discuss hot topics and find innovative solutions. This event provides a unique opportunity for pharmaceutical industry specialists to raise concerns with regulators, exchange experiences and determine the direction of movement in the markets of Central Asia, the Caucasus and Eastern Europe.

Key summit highlights:

  • Leaders’ strategies: the summit participants discussed the development strategies of pharmaceutical companies and their adaptation to various markets in the region.
  • Investment potential: issues of the markets’ investment attractiveness and potential became one of the main topics of the program.
  • Regulatory aspects: regulatory strategies for various markets, issues of registration and re-registration of medicines were in the centre of attention at the summit.
  • Pricing and labelling: issues of approaches to pricing regulation and implementation of drug labelling were raised by attendees at the sessions and round tables.
  • State procurement: different approaches to organising public procurement in the countries of the region were discussed at the summit.
  • Intellectual property protection: protection of intellectual property rights for pharmaceutical drugs remains one of the problematic areas in the region’s pharmaceutical markets.
  • Access of innovative pharmaceutical drugs to markets: conditions for increasing the attractiveness of the region’s markets for the launch of innovative medicines were discussed at the summit.

An important feature of this year’s summit was its interactive formats, including round tables with regulators, master classes and one-to-one meetings with top executives of distribution companies and pharmacy chains.

The contest for the Eurasian Pharma Awards that is organised as a part of the Eurasian Pharmaceutical Summit has become traditional and received 97 applications from pharmaceutical producers, distributors and pharmacy chains from the countries of Central Asia, the Caucasus and Eastern Europe this year. The fifteen winners in various nominations were announced in 2023.

Registration for the Eurasian Pharmaceutical Summit 2024 will open soon. It traditionally will be held in a hybrid format with an offline part in Uzbekistan early autumn. We look forward to meeting the companies that take part in the summit every year and new companies in 2024!

Tatiana Kubasova, Business Development & Frontier Markets Director, AstraZeneca,…

In the dynamic landscape of the pharmaceutical industry, companies that adapt to changing priorities and embrace innovation are poised for success. AstraZeneca, a global leader in the field, has a presence in over 100 countries worldwide, including the diverse markets of Eurasia. Regardless of location, AstraZeneca remains steadfast in its core mission: making innovative medications more accessible to patients.

Today, we have the privilege of speaking with Tatiana Kubasova, Business Development & Frontier Markets Director, AstraZeneca, Russia and Eurasia. She shares insights into the company’s priorities in the Eurasian region, where they see the most promising opportunities, and the pivotal role they play in enhancing patient lives.

Let’s delve into Tatiana’s perspective on AstraZeneca’s strategy and the evolving pharmaceutical landscape in Eurasia.

What are the priorities for your company in the Eurasia region? In which countries and what segments do you see the most prospects for your company?

Today AstraZeneca operates in over 100 countries. In each region the company is focused on creating genuinely innovative medicines and improving access to them. There are millions of people suffering from cardiovascular disease, cancer, and other serious chronic diseases in Eurasia. We firmly believe that modern therapies can improve the quality and life expectancy of these people.

AstraZeneca’s presence in Eurasia comprises Russia, Belarus, Kazakhstan, Uzbekistan, Mongolia, and we’re constantly working to develop our presence in this region. Having started operations in Uzbekistan in 2021, we managed to register several medicines for the treatment of cardiovascular disease, chronic obstructive pulmonary disease, and bronchial asthma. Our next step is to offer the treatment for rare diseases, oncology and oncohematology for patients in Uzbekistan. Above all, we continue to update the existing pipeline with the new indications.

What trends having the most impact on pharmaceutical markets in the countries of the Eurasian region do you highlight for your company?

Today we are witnessing a significant growth in EAEU markets where the pharmaceutical industry was not much developed before, including Uzbekistan. It is due to the low base effect that the market is not yet saturated with the new drugs, which makes it attractive for international companies. We expect the highest growth of the Uzbekistan pharmaceutical market in the next few years.

It is very important to note that the market growth without proper regulation can become dangerous for patients. Hence low-quality medicines can freely enter pharmacies, leading to possible adverse events for the citizens. Therefore, despite the existing prospects, international investors will not be ready to enter the market, given the absence of proper control and compliance for all market players. In this regard, there is an urgent need not only to apply all international requirements and rules of the pharmaceutical industry in Uzbekistan, but also to constantly monitor their compliance. That is why it is necessary to solve the industry regulation issue at the government level, which would ensure the safety of medicines.

What planned regulatory changes may affect the development of the pharmaceutical markets in the Eurasian region?

There is no doubt that the introduction of pharmaceutical drug labelling will have a significant impact on the region’s pharmaceutical market. Russia was the first country in Eurasia to introduce the drug labelling. Therefore, companies that have experience in working with the Russian labelling project will have a technological advantage in other Eurasian markets.

As for Uzbekistan, we expect strengthening of the government regulation in terms of certification and distribution since decent pharmaceutical logistics and distribution is impossible without the abidance by the Good Distribution Practice (GDP) rules, especially considering the region’s climate. Undoubtedly, it is also important to toughen the responsibility of pharmacies for the sale of low-quality and counterfeit medicines.

We are also awaiting the speedy introduction of a health insurance system in Uzbekistan. This will enable a successful investment in the modernization and expansion of the medical care services from diagnosis to access to medicines. Today, patients in Uzbekistan must pay for some services and medicines, which can affect diagnosis and medical care, hence a patient may simply not buy the necessary medication, and therefore not start their treatment. As a result, this may lead to the disease progression and become a heavy burden for the healthcare system in general. That is why we believe that pharmaceutical industry representatives cannot be excluded and must be involved in the pilot projects to boost the timely implementation of the health insurance system in Uzbekistan.

Hayyom Sharapov, CEO, Meros Pharm (Uzbekistan) shared insights on…

In a world of rapidly evolving pharmaceutical markets, companies that can adapt to new challenges and maintain the highest standards of quality stand out. Meros Pharm, a leading pharmaceutical company in Uzbekistan, is one such company. Today, we have the pleasure of hearing from Hayyom Sharapov, CEO, Meros Pharm (Uzbekistan), as he shares his insights on the company’s priorities in the Eurasia region, its strategy for building long-term partnerships, and its ability to adapt to industry changes.

Here’s what he had to say about Meros Pharm’s strategy and prospects.

What are the priorities for your company in the Eurasia region? In which countries and what segments do you see the most prospects for your company?

For Meros Pharm, as the leading pharmaceutical company in Uzbekistan, building long-term relationships with partners is one of the priority strategic directions. We have been working with the leading manufacturers in Eastern Europe and the Caucasus for more than 10 years. For Meros Pharm the main value is to provide the population of Uzbekistan with high-quality, safe medicines, in order to ensure this we select only the most reliable manufacturers of pharmaceutical products.

What trends having the most impact on pharmaceutical markets in the countries of the Eurasian region do you highlight for your company?

Currently, the countries of the Eurasia region are experiencing developments in business culture. Business is becoming more transparent and structured, therefore, by building relationships with partners in Eurasian countries, Meros Pharm is improving its business processes, leveling up its employees’ professionalism and work in accordance with all the requirements and challenges of the contemporary pharmaceutical market.

What planned regulatory changes may affect the development of the pharmaceutical markets in the Eurasian region?

The global economy is currently going through a rather challenging turning point. Let us remember, for example, COVID which taught us to work remotely and other more serious political events taking place in Eurasia. These events do not slow down the development of the legal framework regulating the pharmaceutical market. As we see, all the introduced innovations are aimed at eliminating the import of counterfeit products and regulating prices, as a result, the consumer will receive high-quality pharmaceutical drugs at an affordable price.

Trends in rapidly developing markets: interview with Said Talibov,…

CEO of ASKLEPIY Group Said Talibov in an exclusive interview to the Global Pharmaceutical Leaders’ Club discussed the company’s priorities in the Eurasia region and talked about the trends and regulatory changes in the pharmaceutical markets there.

ASKLEPIY Group is a company engaged in distribution (ASKLEPIY Group and STM Business), retail (OXYmed), production (NIKA PHARM), promotion of pharmaceutical products (MARI PHARM) and production of herbal teas (ZAMONA RANO). The ASKLEPIY Group also includes the tourist recreation area Rano Eco Village.

What are the priorities for your company in the Eurasia region? In which countries and what segments do you see the most prospects for your company?

The main priority for us is developing long-term relationships with our partners, providing quality products of European quality at an affordable price. For many years we have been developing partnerships with key players in the pharmaceutical distribution and retail chains. In a number of countries, our pharmaceutical drugs have already occupied their niches and won their customers, or are being registered at the moment.

ASKLEPIY Group is one of the leading manufacturers in Uzbekistan, we have experience and expertise in this region. Currently, our portfolio is 60% represented by OTC drugs, however, we are constantly innovating, monitoring the market and exploring the prospects for including prescription pharmaceutical drugs manufactured by our company both for the local market and for the other markets in the Eurasia region in our portfolio.

What trends having the most impact on pharmaceutical markets in the countries of the Eurasian region do you highlight for your company?

The Eurasia region is very diverse and it is necessary to be flexible in terms of portfolio decisions and approaches to launches in particular markets and promotion models. The region is booming economically while at the same time legal and regulatory requirements are getting more stringent.

In the region, the standards and quality of patient care are improving, the requirements for the quality of medicines and the need for newer highly effective approaches are increasing. It should also be noted that the market demand is ahead of technological, human and intellectual capabilities. We are facing the situation when training and development of new employees is key to start working in the region.

What planned regulatory changes may affect the development of the pharmaceutical markets in the Eurasian region?

A feature of the Eurasian market as a rapidly developing market is unpredictability. Unpredictability also affects regulatory issues. At the same time, changes and development are undulating.

A number of necessary regulatory documents have now been adopted, including the labeling system. Labeling is the tool that leads to market transparency and is aimed at introducing digitalization. This allows companies to track products from production to the stage when they reach the customer. The introduction of reference pricing makes it possible to take more care of the consumer as it allows to prevent the situation of excessive markup on certain products when there is a lack of pharmaceutical drugs in the market. Also in the medium term, we can expect the introduction of health insurance systems in a number of countries. This will certainly affect the model of medical care, the procurement procedure, and approaches to pharmaceutical drug provision.

Strategic prospects and development: An Interview with Vladislav Bessarabov,…

Global Pharmaceutical Leaders’ Club presents an interview with Vladislav Bessarabov, Head of Strategic Business Unit Eurasia at Bosnalijek. Let’s look into the future of the pharmaceutical market and find out what plans and priorities are embedded in the company’s development strategy.

Vladislav Bessarabov shared his insights on the future of the company in the Eurasian region. The interview delved into the following questions:

  • What are the priorities for your company in the Eurasia region? In which countries and in what segments do you see the greatest prospects for your company?
  • What trends that have a significant impact on the markets in the Eurasia region do you highlight for your company?
  • What planned regulatory changes may affect the development of the pharmaceutical markets in the Eurasian region?

Vladislav Bessarabov emphasized the importance of understanding the dynamics of the market development and the readiness to adapt to new challenges. He expressed confidence in the successful future of Bosnalijek in the Eurasia region and invites to discuss possible collaboration at the Eurasian Pharmaceutical Summit.

What are the priorities for your company in the Eurasia region? In which countries and what segments do you see the most prospects for your company?

Being focused on sustainable and dynamic development, Bosnalijek prioritizes the entire Eurasia region where we have been building partnerships with key players in pharmaceutical distribution and retail for several years. In many countries our pharmaceutical drugs have already firmly occupied their niches, either entering the market or being registered. Now Bosnalijek is represented mainly by non-prescription medicines but we are constantly monitoring the market and studying the prospects for including prescription pharmaceutical drugs from a wide range of products manufactured by our company into the country portfolio. Fortunately, the European approach to quality and safety control, compliance with the requirements of good manufacturing practice, and, most importantly, flexibility in pricing and commercial policy, allow us to create interesting and sought-after offers for both business partners and the end users.

What trends having the most impact on pharmaceutical markets in the countries of the Eurasian region do you highlight for your company?

Over the past year, the economies of most countries in the region received a strong boost thanks to sharply increased imports and re-exports, as well as additional incoming foreign exchange flows. All this, in turn, forces the business to look for new opportunities for ‘parking’ money in the form of reliable investments, and the pharmaceutical market is just such a promising direction. We expect an increase in competition not only between international manufacturers, but also the entry of local players into the most promising segments of the pharmaceutical market as its full participants, and possibly drivers. In any case, we plan to actively invest in development and gain market shares in the segments and countries of interest to us.

What planned regulatory changes may affect the development of the pharmaceutical markets in the Eurasian region?

The current landscape of the regional markets is very diverse, so we have to face many challenges and build our business policy in a multi-vector format. Thus, presence in the Eurasian region requires taking into account the simultaneous initiatives of different countries to regulate pricing, change registration requirements, introduce labeling procedures, as well as transport and logistics transformations. Today this multi-vector approach to planning is the only possible form of work that requires significant involvement, awareness and return. That is why the platform of the Eurasian Pharmaceutical Summit is an excellent opportunity for the exchange of information and best practices between market participants.

Opening the Doors to the World of Health: Interview…

Global Pharmaceutical Leaders Club is pleased to announce an exclusive interview with Hakan Erturk, a leading expert and CEO of Solgar Russia & CIS region, who shares his insights and plans for development in the growing markets of the Eurasia region.

Health as the Main Priority: Modern society is increasingly striving for a healthy lifestyle, and Solgar is focused on providing quality products that contribute to well-being. We will tell you about the countries and health segments that Hakan Erturk sees as the most promising.

Trends Shaping the Future: Hakan Erturk provides his perspective on trends influencing health and pharmaceutical markets in the Eurasia region. He will discuss the growing interest in disease prevention and innovative products that cater to the needs of modern consumers.

Regulations and Challenges: Market development is always connected with regulatory changes. What innovations are expected, and how is Solgar preparing for them? Hakan Erturk provides an overview of planned changes and explains how the company plans to maintain the high quality of its products.

Hakan Erturk is an inspiring figure, closely monitoring trends and regulations in the world of pharmaceuticals. His opinions and experience serve as valuable guides for the successful development of Solgar in the territories of Russia and the CIS.

What are the priorities for your company in the Eurasia region? In which countries and what segments do you see the most prospects for your company?

In our business, we pay significant attention to the development of nutrient intake culture. Moreover, not only among the population but also within the pharmaceutical community because nowadays this segment is rapidly developing in the world as a separate category. We see development prospects in such countries as Uzbekistan, Kazakhstan, Kyrgyzstan, Azerbaijan and Armenia.

What trends having the most impact on pharmaceutical markets in the countries of the Eurasian region do you highlight for your company?

The main trend that we see is the growing interest in nutritional support, namely the regular intake of dietary supplements on a daily basis. Globally, tangible increase occurred during and after the pandemic, including among healthcare professionals. The intake and use of dietary supplements in traditional medical practice is especially discussed, to reduce the burden on the healthcare system by focusing on certain categories of chronic diseases.

What planned regulatory changes may affect the development of the pharmaceutical markets in the Eurasian region?

We highlight such problematic areas as regulation of cross-border trade when it comes first of all to consumer safety, adaptation of the level of allowable daily dosages in accordance with international standards, customs duties for some countries where they are significantly overestimated, not only for imports, but also export and purchase of raw materials.

Marcus Sieger

Innovation Leadership and Global Impact: Interview with Markus Sieger,…

Markus Sieger, CEO of Polpharma Group in an exclusive interview with the Global Pharmaceutical Leaders’ Club discussed priorities and prospects for the company’s development in the Eurasia region and regulatory changes that have the greatest impact on the development of the pharmaceutical markets in the countries of Central Asia, the Caucasus and Eastern Europe.

SANTO, a member of Polpharma Group, is one of the leaders in the pharmaceutical markets of the Eurasian region. Due to its cutting-edge technology and unique expertise, the company has earned a reputation of the innovation leader with global influence.

What are the priorities for your company in the Eurasia region?

SANTO is the leading pharmaceutical manufacturer in Central Asia and part of the European group of companies Polpharma, which produces effective, safe and affordable pharmaceutical drugs for the treatment of diseases in 12 pharmacotherapeutic groups. All production and warehousing of the company has GMP certificates of the EAEU and the Republic of Kazakhstan. Our R&D laboratory is one of the best in Central Asia. It develops various types of medicines and implements research programs. This is the unique feature of SANTO among other pharmaceutical companies as we do not do a simple technology transfer, we not only import, but also develop our own generic medicines.

The priority of SANTO is to expand the portfolio of medicines, considering the needs of local markets, increasing its presence in the following countries: Uzbekistan, Kyrgyzstan, Mongolia, Turkmenistan, Tajikistan, Afghanistan and others. Our experts have a clear understanding of the demand for medicines of various forms and dosages and make every effort to meet the needs of the healthcare systems.

We have initiated the “GO WEST!” project aimed at developing a Central Asian pharmaceutical hub out of Shymkent creating a contemporary R&D and quality control center and passing the European Union inspection to obtain a GMP certificate for our production site. With this certificate the company plans to start exporting its medicines to the EU countries.

What trends having the most impact on pharmaceutical markets in the countries of the Eurasian region do you highlight for your company?

After the pandemic, people began to realize that health is the most important and valuable for each of us. Therefore, more and more people want to switch to a healthy lifestyle. In this vein, our goal is to help them stay healthy for as long as possible and prevent the development of diseases. People’s immune systems have weakened, so we began to produce more nutritional supplements, vitamins and other products that help a person maintain good health and prevent diseases. This is the first trend to which we respond.

Basically, we see an increasing demand for medicines, which is the second trend. In the US and Germany, as you know, 80% of medicines are generics. In our company, we also produce mainly generics. As a firm rule, they are less expensive and more accessible to the population. Therefore, we believe that the expansion of the production of such drugs in Kazakhstan will allow more people to receive the necessary quality treatment in the countries of Central Asia.

We believe that generic medicine is the best solution for healthcare providers, as the Central Asian countries have a limited amount of funds to spend on medicines. The need and use of medicines is constantly growing in so called emerging markets. With the development of the health insurance system in the countries of our region the pharma markets will increase both in volume and value of medicines. This creates opportunities to develop our portfolio and sales in the region.

As an example, over all these years we have invested about $108 million in SANTO, and by 2025 we will increase this figure to $130 million. Now we are finishing our project to develop a new R&D and testing center at the plant in Shymkent. There will be the most advanced technologies that meet European standards. This will be the first plant in Central Asia that will produce medicines according to European standards. We trust that countries of the region will move towards high quality GMP standard medicines as the base for their patients’ treatment.

What planned regulatory changes may affect the development of the pharmaceutical markets in the Eurasian region?

The region of Eurasia has been on the path of unification of the regulatory standards since January 2015.

The ambition than was to create one common regulatory system within the Eurasian Union which covered some of the countries of the region (Kazakhstan, Russia, Kyrgyzstan and Armenia). This effort has led to common regulatory requirements, common GMP standards and rules of circulation of medicines. One of key elements was to introduce the mutual recognition process in granting marketing authorizations which would be the advantage for manufacturers. This was only partially successful – the procedure does not work quite as expected.

This effort has resulted in some success and upgrade of registration dossiers and manufacturing processes. As not all the countries are part of Eurasian Economic Union, they develop their own regulatory pathways referring to EMA, ICH, FDA or have legacy system.

As an example: we see in Uzbekistan a trend to feature on EMA and ICH, but legal acts do not fully respect European regulations. Most recently in January Uzbekistan has introduced new registration principles which penalizes European manufacturers who are not on the Waiver List.

This list was compiled incorrectly; not all European countries with production facilities that fully comply with the requirements of European standards were included in it. This indicates the imperfection of existing legal acts.

This affect EU manufacturers like Polpharma that will experience the delays in introducing new products to UZ market and market will experience out-of-stock situation for the patients. We are truly disappointed with this regulatory change. We believe that this type of regulatory changes limits the growth of the markets and reduces their attractiveness in the region. We hope that in the future we will be able to avoid such situations, because the good of the patient should come first.

Arminas Macevicius

Development of pharmaceutical markets in Eurasia: Insights from the…

Arminas Macevicius, Vice President Eurasia at Stada in an exclusive interview to the Global Pharmaceutical Leaders’ Club discussed the company’s priorities in the Eurasia region, development prospects, current trends and regulatory changes affecting pharmaceutical markets.

In the interview with Arminas Macevicius, we covered the following questions:

– What are the priorities for your company in Eurasia?
– What trends having the most impact on pharmaceutical markets in the countries of Eurasia do you highlight for your company?
– What planned regulatory changes may affect the development of the pharmaceutical markets in Eurasia?

What are the priorities for your company in the Eurasia region?

With the addition of Sanofi products to STADA’s portfolio in Eurasia, we have strengthened our position in the CHC (Consumer Healthcare) segment even further. Of course, we will continue developing this area through investments and possibly by attracting partners such as Sanofi. Over the next few years, the company intends to strengthen its position in the hospital segment and prescription business. In the countries of Eurasia where there is a recognition and / or simplified procedure (for instance, in Moldova, Uzbekistan, Georgia), we have already registered a number of new European prescription pharmaceutical drugs. We will continue this work, as well as collaborate with the regulatory authorities of all our countries to further simplify the market access procedure. In the medium and long term perspective, we are planning to develop the biosimilars segment which along with generics is one of the key businesses for STADA. I believe that within 1 to 1.5 years we will be able to offer such medicines to those markets in Eurasia where there is an accelerated registration.

What trends having the most impact on pharmaceutical markets in the countries of the Eurasian region do you highlight for your company?

In addition to the rather high unpredictability of the Eurasian markets in general, the pharmaceutical industry faces logistical and production issues. This is the lack of storage facilities, and the limited production sites potentially suitable for contract manufacturing, and difficulties with the status of the EAEU including the situation when not all the countries in Central Asia are its members.

I still stand up for the simplification and acceleration of procedures, for the unification of approaches to the registration of products, for recognizing pharmaceutical drugs as local for the needs of public procurement. All Central Asian countries are demonstrating impressive population growth, only the combination of the largest markets, Kazakhstan and Uzbekistan, gives us a total market of more than 60 million people. It is obvious that mechanisms that would allow considering Central Asia as a single market are needed. This would make it much easier for many companies to make investment decisions, including those related to the localization of the production of innovative pharmaceutical drugs. Ultimately, everyone will benefit from this: regulators, healthcare professionals, and, most importantly, patients.

What planned regulatory changes may affect the development of the pharmaceutical markets in the Eurasian region?

The authorities of the countries in the Eurasia region are already doing a lot to improve the quality of medical care and medicines provision. For example, in Kazakhstan, the market share of public procurement is more than 40%. This is now one of the best indicators in Eurasia. I have mentioned before the recognition procedures in a number of countries. It is possible that the introduction of combined systems, the development of insurance, and co-payment will help improve key health indicators and availability of medicines for the population.

Unleashing success in pharma: An interview with Elena Bushberg,…

In the ever-changing world of the pharmaceutical industry, companies’ leaders face relentless challenges head-on to success. In the interview, we spoke with Elena Bushberg, Executive Director of Olainfarm, one of the leading pharmaceutical companies in the Eurasia region, about her views on the current situation in the Eurasia region and the future of the industry.
In the interview with Elena Bushberg, we discussed the following questions:

– What are the priorities for your company in Eurasia?
– What trends having the most impact on pharmaceutical markets in the countries of Eurasia do you highlight for your company?
– What planned regulatory changes may affect the development of the pharmaceutical markets in Eurasia?

What are the priorities for your company in the Eurasia region?

Olainfarm is driven by a profound commitment to deliver high quality therapies in the fields of neurology, cardiology, urology, and other therapeutic areas. Our ultimate goal is to enhance the health and improve the quality of life for our patients.

In our pursuit of supporting healthcare professionals, pharmacists, and patients, we are continuously expanding our product portfolio. As the leading pharmaceutical company in the Baltics, we strive to make significant investments in research and development, modernize our facilities, increase our production capacity, and embrace digitalisation processes. These efforts enable us to deliver the essential treatments and therapies needed for the well-being and improved health outcomes of our patients. By staying at the forefront of innovation and technology, we are able to meet the evolving needs of the healthcare industry and make a positive impact on the lives of individuals across the region.

As a socially responsible enterprise, Olainfarm goes beyond its core mission by actively engaging in education initiatives. We are dedicated to making a positive impact in the communities we serve, particularly in Central Asia. Through our support of local initiatives and social projects like “Cosmic Calmness” in Uzbekistan, we strive to change the culture of health awareness and empower individuals to improve their quality of life and life expectancy.

What trends having the most impact on pharmaceutical markets in the countries of the Eurasian region do you highlight for your company?

The Eurasian region is experiencing rapid economic growth and technological advancements. We are witnessing a significant transformation in diagnostics and treatment practices, with a growing number of individuals becoming more conscious of their health. That is a positive trend as it ensures that people can live healthier and longer lives improving their quality and wellbeing. As a key player in the healthcare industry, we are actively contributing to these changes in our respective fields.

In Uzbekistan, we have observed a strong emphasis on population health, with the government and ministries prioritizing access to medicines and healthcare services for the people. These emerging trends have a profound impact on the development of the pharmaceutical market and play a crucial role in shaping our investment decisions related to these countries.

We embrace the opportunities presented by this dynamic region, recognizing the potential for collaboration and innovation. By aligning our strategies with the evolving healthcare landscape, we aim to enhance patient outcomes and contribute to the overall well-being of communities. Our dedication to delivering high-quality therapies and our commitment to sustainable growth are at the forefront of our decision-making process.

What planned regulatory changes may affect the development of the pharmaceutical markets in the Eurasian region?

We closely monitor changes in pricing regulations in all countries we operate, as overregulated markets usually experience stagnation, which lack positive dynamics.

Serialization is also one of our key areas of focus. In fact, Olainfarm was the first European company to successfully transition to serialized product shipments to Uzbekistan. We are confident that we will be well-prepared to ensure timely delivery of serialized products to Kazakhstan and Kyrgyzstan as well.

Furthermore, we pay close attention to developments within the Eurasian Economic Union (EAEU), as regulatory changes within this economic community have a significant impact on the pharmaceutical markets of this region.

© Global Pharmaceutical Leaders' Club